Aethlon CEO Joyce discusses novel Ebola strategy
Joyce said the current Ebola outbreak in West Africa shows the necessity for therapeutic strategy to defend against pandemic threats. He said the company's Hemopurifier could serve as a broad-spectrum countermeasure against emerging threats like Ebola and other threats that could be weaponized through bioterrorism.
"At Aethlon Medical, we are intersecting advanced biology with modern plasma membrane technology to rethink the treatment of viral pathogens," Joyce said. "The result is the Aethlon Hemopurifier, a therapeutic device that has been validated to capture a broad-spectrum of viral pathogens and immunosuppressive proteins through affinity binding to a unique high-mannose structure that is co-opted from the host (the infected individual) as a means for viruses to evade detection of the host immune system."
In 2007, a CDC report discussed the potential of the Hemopurifier as a treatment countermeasure against Ebola and other filoviruses. Future studies by the U.S. Army Medical Research Institute for Infectious Diseases found the Hemopurifier captured approximately 50 percent of both wild-type and mutant strains of the Zaire strain of Ebola from fluids during one hour.
Joyce said that Aethlon is investigating emergency use authorization approvals based on previous studies against viral pathogens.
"I want to share that we have initiated our dialog with (the Food and Drug Administration)," Joyce said. "The results of these discussions will determine whether we request an opportunity to treat those infected with Ebola virus."
Aethlon develops medical devices that address life-threatening diseases.